Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYMAKER-U02 Substudy 02D in melanoma with brain metastases
MOH_2021-04-13_009762Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of quavonlimab + pembrolizumab, pembrolizumab and lenvatinib in melanoma (4 cohorts), sponsored by Merck & Co. Primary endpoints: Safety and tolerability and Objective response rate. Started Jan 2021; status: completed.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on MOH_2021-04-13_009762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-04-13_009762.